Comparable stake leader
Third Rock Ventures V, L.P.
SEC ownership of Rapport Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002012593.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- RAPP on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Third Rock Ventures V, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Third Rock Ventures V, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0002012593
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Rapport Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Third Rock Ventures V, L.P.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 13%
13D/G row: Third Rock Ventures V, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Third Rock Ventures V, L.P. leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Third Rock Ventures V, L.P.'s linked filing trail.
Comparable ownership
Top 5
Third Rock Ventures V, L.P.
13%
Capital International Investors
6.1%
Cormorant Asset Management, LP
5.6%
BlackRock, Inc.
5%
JOHNSON & JOHNSON
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. |
3/4/5
13D/G
10%+ Owner
|
13%
from 13D/G
|
$281,843,015
7,249,743 shares
|
-$34,391,226 | 26 May 2026 |
| Capital International Investors |
13F
13D/G
Company
|
6.1%
from 13D/G
|
$121,757,990
2,921,958 shares
|
— | 30 Jun 2026 |
| Cormorant Asset Management, LP |
13D/G
13F
Company
|
5.6%
|
$110,738,900
2,657,521 shares
|
-$12,501,000 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$112,500,083
2,699,786 shares
|
— | 30 Jun 2026 |
| JOHNSON & JOHNSON |
13F
13D/G
Company
|
4.9%
from 13D/G
|
$74,360,823
1,784,517 shares
|
— | 30 Jun 2026 |
| Sofinnova Venture Partners XI, L.P. |
13D/G
Dr. James I. Healy ("Healy")
|
4.2%
|
$29,155,258
1,947,579 shares
|
$0 | 11 Sep 2025 |
| Third Rock Ventures GP V, LP |
3/4/5
10%+ Owner
|
15%
|
$281,843,015
7,249,743 shares
|
-$34,391,226 | 26 May 2026 |
| Third Rock Ventures GP VI, L.P. |
3/4/5
10%+ Owner
|
15%
|
$281,843,015
7,249,743 shares
|
-$34,391,226 | 26 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$215,819,451.
Buys
$1,605,585
Insiders: 3
Sells
$217,425,036
Insiders: 10
Net
-$215,819,451
Shares: -5,402,211
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 65,566
Shares: 5,467,777
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 191,975 | $0 | $8,080,546 | -$8,080,546 |
| 3-6 | 0 | 5,079,395 | $0 | $204,045,545 | -$204,045,545 |
| 6-9 | 0 | 72,655 | $0 | $2,092,035 | -$2,092,035 |
| 9-12 | 65,566 | 123,752 | $1,605,585 | $3,206,909 | -$1,601,324 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Rapport Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
TRV GP V, LLC
Net 12M change
-$215,819,452
Latest report
19 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| TRV GP V, LLC | 10%+ Owner | $281,843,015 | -$34,391,226 | -11% | Mixed | 26 May 2026 |
| Third Rock Ventures V, L.P. | 10%+ Owner | $281,843,015 | -$34,391,226 | -11% | Mixed | 26 May 2026 |
| Third Rock Ventures GP VI, L.P. | 10%+ Owner | $281,843,015 | -$34,391,226 | -11% | Mixed | 26 May 2026 |
| Third Rock Ventures VI, L.P. | 10%+ Owner | $281,843,015 | -$34,391,226 | -11% | Mixed | 26 May 2026 |
| TRV GP VI, LLC | 10%+ Owner | $281,843,015 | -$34,391,226 | -11% | Mixed | 26 May 2026 |
| Third Rock Ventures GP V, LP | 10%+ Owner | $281,843,015 | -$34,391,226 | -11% | Mixed | 26 May 2026 |
| ARCH Venture Partners XII, LLC | 10%+ Owner | $37,212,805 | Mixed | 10 Jun 2024 | ||
| Abraham Ceesay | Chief Executive Officer, Director | $27,905,404 | -$6,678,997 | -19% | Mixed | 10 Aug 2026 |
| James Healy | Director | $19,916,028 | Mixed | 10 Jun 2026 | ||
| Krishnaswamy Yeleswaram | Chief Development Officer | $12,276,497 | -$1,926,088 | -14% | Filing P/S | 19 Aug 2026 |
| Cheryl Gault | Chief Operating Officer | $6,469,493 | -$906,406 | -12% | Filing P/S | 30 Jun 2026 |
| Bradley S. Galer | Chief Medical Officer | $1,970,311 | Mixed | 06 Jun 2024 | ||
| Steven M. Paul | Director | $1,040,450 | +$1,027,111 | +7700% | Filing P/S | 10 Jun 2026 |
| David Bredt | Chief Scientific Officer | $707,535 | -$1,566,190 | -69% | Mixed | 17 Feb 2026 |
| Reid M. Huber | Director | $499,373 | +$499,374 | +100% | Filing P/S | 10 Jun 2026 |
| Wendy B. Young | Director | $214,700 | +$79,100 | +58% | Filing P/S | 10 Jun 2026 |
| Troy A. Ignelzi | Chief Financial Officer | $99,800 | Filing P/S | 02 Feb 2026 | ||
| Ramiro Sanchez | Director | Mixed | 10 Jun 2026 | |||
| Jeffrey K. Tong | Director | Mixed | 06 Jun 2024 | |||
| Paul M. Silva | Director | Mixed | 10 Jun 2026 |
Recent insider transactions for Rapport Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -0.16% | $20,160 | $49.90 | -404 | 246,022 | 19 Aug 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -5.62% | $1,390,405 | $48.01 | -28,958 | 486,108 | 11 Aug 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -4.19% | $1,042,772 | $46.26 | -22,541 | 515,066 | 10 Aug 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -0.41% | $93,061 | $42.11 | -2,210 | 537,607 | 27 Jul 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -1.5% | $328,437 | $40.00 | -8,210 | 539,817 | 14 Jul 2026 | Direct |
| Cheryl Gault | RAPP | Common Stock | Sale | -6.25% | $415,798 | $41.58 | -10,000 | 149,914 | 30 Jun 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -1.48% | $327,398 | $39.83 | -8,220 | 548,027 | 29 Jun 2026 | Direct |
| John Maraganore | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Robert J. Perez | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Steven M. Paul | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Paul M. Silva | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| James Healy | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Reid M. Huber | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Wendy B. Young | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Ramiro Sanchez | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | $743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | $743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | $743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | $743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | $743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | $743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -2.08% | $5,377,323 | $40.24 | -133,618 | 6,299,097 | 11 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -2.08% | $5,377,323 | $40.24 | -133,618 | 6,299,097 | 11 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -2.08% | $5,377,323 | $40.24 | -133,618 | 6,299,097 | 11 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -2.08% | $5,377,323 | $40.24 | -133,618 | 6,299,097 | 11 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -2.08% | $5,377,323 | $40.24 | -133,618 | 6,299,097 | 11 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -2.08% | $5,377,323 | $40.24 | -133,618 | 6,299,097 | 11 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.08% | $202,256 | $40.31 | -5,018 | 6,432,715 | 08 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.08% | $202,256 | $40.31 | -5,018 | 6,432,715 | 08 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.08% | $202,256 | $40.31 | -5,018 | 6,432,715 | 08 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.08% | $202,256 | $40.31 | -5,018 | 6,432,715 | 08 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.08% | $202,256 | $40.31 | -5,018 | 6,432,715 | 08 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.08% | $202,256 | $40.31 | -5,018 | 6,432,715 | 08 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -4.05% | $10,892,651 | $40.12 | -271,495 | 6,437,733 | 07 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -4.05% | $10,892,651 | $40.12 | -271,495 | 6,437,733 | 07 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -4.05% | $10,892,651 | $40.12 | -271,495 | 6,437,733 | 07 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -4.05% | $10,892,651 | $40.12 | -271,495 | 6,437,733 | 07 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -4.05% | $10,892,651 | $40.12 | -271,495 | 6,437,733 | 07 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -4.05% | $10,892,651 | $40.12 | -271,495 | 6,437,733 | 07 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -5.97% | $17,175,244 | $40.32 | -426,005 | 6,709,228 | 17 Apr 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -5.97% | $17,175,244 | $40.32 | -426,005 | 6,709,228 | 17 Apr 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -5.97% | $17,175,244 | $40.32 | -426,005 | 6,709,228 | 17 Apr 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -5.97% | $17,175,244 | $40.32 | -426,005 | 6,709,228 | 17 Apr 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -5.97% | $17,175,244 | $40.32 | -426,005 | 6,709,228 | 17 Apr 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -5.97% | $17,175,244 | $40.32 | -426,005 | 6,709,228 | 17 Apr 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -7.58% | $808,844 | $39.99 | -20,225 | 246,426 | 17 Apr 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -3.68% | $357,797 | $35.08 | -10,200 | 266,651 | 14 Apr 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -3.2% | $320,537 | $34.97 | -9,165 | 276,851 | 13 Apr 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -0.17% | $17,490 | $34.98 | -500 | 286,016 | 10 Apr 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -0.13% | $12,564 | $34.90 | -360 | 286,516 | 08 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.